Skip to content
Clinical Trials – home
Therapeutic area

Gastrointestinal disorders – page 8

  • 1 133 clinical trials
  • 489 recruiting
  • 474 conditions
  • 28 countries

Conditions in this area

474 conditions with trials, the busiest first

Clinical trials in Gastrointestinal disorders

1 133 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 133 clinical trials

Gastric cancer+2

Recruiting

A study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A long-term safety study of KYV-101 in patients previously treated for lupus nephritis, systemic sclerosis, myasthenia gravis, rheumatoid arthritis, or stiff person syndrome

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:KYV-101
  • Sponsor:Kyverna Therapeutics Inc.

Using 68Ga-FAPI-46 imaging to detect fibrosis in patients with inflammatory diseases such as Crohn's disease, ulcerative colitis, systemic sclerosis, and lung fibrosis.

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Amsterdam UMC Stichting

Study of the safety and use of the Extroducer infusion catheter system for delivering gemcitabine to patients with unresectable locally advanced pancreatic cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Smartwise Sweden AB

A study comparing the effectiveness of a simeticone drug combination and a sodium picosulfate drug combination for bowel preparation in patients undergoing colorectal cancer screening.

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Citric Acid
  • Sponsor:Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer

A study to evaluate the efficacy and safety of etrasimod arginine in children with moderately to severely active ulcerative colitis

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Etrasimod Arginine
  • Sponsor:Pfizer Inc.

A Study to Evaluate LY3537021 and a Drug Combination for Treating Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Aprepitant
  • Sponsor:Eli Lilly & Co.

A study to evaluate the safety and effects of inebilizumab in children and adolescents with immunoglobulin G4-related disease

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Inebilizumab
  • Sponsor:Amgen Inc.

Gastric cancer+2

Recruiting

A study to evaluate the use of FAPI-46 (68Ga) imaging to detect peritoneal cancer spread in patients with colorectal, gastric, ovarian, or pancreatic cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:GE Healthcare Limited

Still's disease+1

Recruiting

A study to evaluate the long-term safety of apremilast in children with oral ulcers from Behçet’s disease or juvenile psoriatic arthritis

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years
  • Substances:Apremilast
  • Sponsor:Amgen Inc.

Evaluation of Safety and Efficacy of MK-2870 and Paclitaxel in Second-Line Treatment of Advanced/Metastatic Gastroesophageal Adenocarcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Merck Sharp & Dohme LLC

Substances studied in this area

The therapies tested most often in Gastrointestinal disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.